Companies to learn what they must pay EMA in pharmacovigilance fees
This article was originally published in SRA
Executive Summary
Pharmaceutical companies with nationally authorized products on the EU market will find out soon what the European Medicines Agency thinks their annual pharmacovigilance fee should be1.